Eli Lilly has been granted approval in the EU for Amyvid, a solution to diagnose Alzheimer’s disease.

Amyvid (florbetapir [18F]) is used as an imaging agent during positron emission tomography (PET) scanning to detect the presence or absence of beta-amyloid plaques in the brains of adult patients with cognitive impairment.
At the moment, doctors rely only on a clinical evaluation to decide whether patients with cognitive impairment are suffering from Alzheimer’s disease or some other cause of cognitive decline, so being able to see whether amyloid plaques are present in the brain will help the accuracy of diagnosis.

More information at the link below:




January 20, 2013